http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101166523-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41 |
| filingDate | 2006-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f16d717ed95e259de44ce82392af486f |
| publicationDate | 2008-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-101166523-A |
| titleOfInvention | Methods of treating atherosclerosis |
| abstract | The present invention relates to a method for the prevention, delay the onset and treatment of atherosclerosis which method comprises administering to a warm-blooded animal, in need thereof, a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with at least one therapeutic agent selected from the group consisting of: (1) an ACE inhibitor, or a pharmaceutically acceptable salt thereof; (2) an angiotensin II receptor blocker, or a pharmaceutically acceptable salt thereof; (3) a diuretic, or a pharmaceutically acceptable salt thereof; (4) a calcium channel blocker (CCB), or a pharmaceutically acceptable salt thereof; (5) a beta-blocker, or a pharmaceutically acceptable salt thereof; (6) a platelet aggregation inhibitor, or a pharmaceutically acceptable salt thereof; (7) a cholesterol absorption modulator, or a pharmaceutically acceptable salt thereof; (8) a HMG-Co-A reductase inhibitor, or a pharmaceutically acceptable salt thereof; and (9) a high density lipoprotein (HDL) increasing compound, or a pharmaceutically acceptable salt thereof. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102247346-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102316856-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102146473-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102146473-B |
| priorityDate | 2005-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 306.